ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Maravai Lifesciences Holdings, Inc. ?
1
The company has declared positive results in Mar'2026 after 5 consecutive negative quarters
- NET PROFIT(HY) Higher at USD 17.43 MM
- OPERATING PROFIT(Q) Highest at USD 15.45 MM
- OPERATING PROFIT MARGIN(Q) Highest at 23.47 %
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 135.19%, its profits have fallen by -6.1%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 135.19% in the last 1 year, much higher than market (S&P 500) returns of 20.34%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Maravai Lifesciences Holdings, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Maravai Lifesciences Holdings, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Maravai Lifesciences Holdings, Inc.
135.19%
-0.55
71.91%
S&P 500
20.34%
1.56
13.03%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-8.15%
EBIT Growth (5y)
-194.50%
EBIT to Interest (avg)
8.08
Debt to EBITDA (avg)
0.39
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0.35
Tax Ratio
0.67%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
54.71%
ROE (avg)
64.89%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.46
EV to EBIT
-10.54
EV to EBITDA
-47.51
EV to Capital Employed
2.77
EV to Sales
4.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.25%
ROE (Latest)
-43.31%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
NET PROFIT(HY)
Higher at USD 17.43 MM
OPERATING PROFIT(Q)
Highest at USD 15.45 MM
OPERATING PROFIT MARGIN(Q)
Highest at 23.47 %
PRE-TAX PROFIT(Q)
Highest at USD -1.9 MM
RAW MATERIAL COST(Y)
Fallen by -224.02% (YoY
NET SALES(Q)
Highest at USD 65.84 MM
EPS(Q)
Highest at USD -0.03
-9What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -39.52 MM
NET PROFIT(Q)
At USD 0.9 MM has Fallen at -55.05%
CASH AND EQV(HY)
Lowest at USD 382.81 MM
Here's what is working for Maravai Lifesciences Holdings, Inc.
Net Sales
At USD 65.84 MM has Grown at 41.78%
over average net sales of the previous four periods of USD 46.44 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD 15.45 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 23.47 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -1.9 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -1.9 MM has Grown at 92.12%
over average net sales of the previous four periods of USD -24.05 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Sales
Highest at USD 65.84 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
EPS
Highest at USD -0.03
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -224.02% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Maravai Lifesciences Holdings, Inc.
Net Profit
At USD 0.9 MM has Fallen at -55.05%
over average net sales of the previous four periods of USD 2 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Cash Flow
Lowest at USD -39.52 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Cash and Eqv
Lowest at USD 382.81 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
